Asthma
Asthma Management
search
Asthma Management
, Asthma Stepped Care, Asthma Stepwise Management
See Also
Asthma
Asthma Evaluation
Asthma Differential Diagnosis
Asthma Education
Asthma Exacerbation
Asthma Exacerbation Home Management
Emergency Management of Asthma Exacerbation
Asthma Inpatient Management
Status Asthmaticus
Management
Strategy
Written action plan
Based on symptoms or
Peak Expiratory Flow
Long term use of
Inhaled Corticosteroid
s (persistent
Asthma
)
Decrease airway inflammation
Most effective medication for long-term control
Add long acting
Bronchodilator
for moderate to
Severe Asthma
Intermittent and cautious use of
Inhaled Beta Agonist
Avoid more than 4 times per day
Regular use beyond
Exercise
-related should prompt reevaluation to step-up therapy (see below)
Consider
Asthma
-contributers (Mnemonic: Air-Smog)
Allergans (pets,
Dust mite
s, molds, pollens)
Irritants and Infections
Rhinitis
(allergic) or
Sinusitis
(acute or chronic)
Smoking,
Sleep Apnea
or Stress
Medications (
Beta Blocker
s,
Aspirin
,
NSAID
S)
Occupational
Gastroesophageal Reflux
Disease
Prevent
Exercise
-induced and cold-induced
Asthma
See
Exercise
Induced
Asthma
Consider sodium
Cromoglycate
Management
Approach to Uncontrolled Symptoms
Indicators of uncontrolled
Asthma
Frequent use and early refills of rescue
Inhaler
Rescue
Inhaler
use more than twice weekly
Awakening with nighttime symptoms more than twice monthly (over age 5)
Within last 12 months, two or more courses of oral
Corticosteroid
s, or
Asthma
hospital admission
Assessment
Consider
Asthma
control test (see resources below)
Review
Asthma
medication use and
Asthma Action Plan
Confirm compliance
Patient should demonstrate use of their rescue
Inhaler
(and with spacer)
Obtain
Spirometry
at time of diagnosis and and consider repeating at times of worsening
Asthma
control
Protocol
Advance medications per stepped care and
Asthma
grouping (see below)
For more significant symptoms start at a higher step (e.g. step 3 or 4)
Re-evaluate every 2-4 weeks and step-up or step down management
Advance stepped care for short-acting
Bronchodilator
more than twice weekly for acute symptom control
Step 1:
Mild Intermittent Asthma
Inhaled short-acting
Bronchodilator
(
SABA
) as needed
Step 2:
Mild Persistent Asthma
Inhaled short-acting
Bronchodilator
(
SABA
) as needed
Add low dose
Inhaled Corticosteroid
(ICS)
Step 3:
Moderate Asthma
Inhaled short-acting
Bronchodilator
(
SABA
) as needed
Option 1
Change low dose to moderate dose
Inhaled Corticosteroid
(ICS)
Option 2
Continue low dose
Inhaled Corticosteroid
(ICS) AND
Add long-acting
Bronchodilator
(
LABA
)
Option 3
SMART Asthma Management Protocol
Step 4:
Moderate Asthma
See
SMART Asthma Management Protocol
Inhaled short-acting
Bronchodilator
(
SABA
) as needed
Change to Moderate dose
Inhaled Corticosteroid
(ICS)
Long-acting
Bronchodilator
(
LABA
)
Step 5:
Severe Asthma
See
SMART Asthma Management Protocol
Inhaled short-acting
Bronchodilator
(
SABA
) as needed
Change to High dose
Inhaled Corticosteroid
(ICS)
Long-acting
Bronchodilator
(
LABA
)
Consider
Long-Acting Muscarinic Antagonist
(
LAMA
)
Consider
Leukotriene Receptor Antagonist
(LTRA)
Consider
Biologic Agent
(e.g.
Omalizumab
) in patients with allergies
Step 6:
Severe Asthma
See
SMART Asthma Management Protocol
Inhaled short-acting
Bronchodilator
(
SABA
) as needed
High dose
Inhaled Corticosteroid
(ICS)
Long-acting
Bronchodilator
(
LABA
)
Long-Acting Muscarinic Antagonist
(
LAMA
)
Consider
Biologic Agent
(e.g.
Omalizumab
) in patients with allergies
Consider Oral
Systemic Corticosteroid
s
Additional measures
See
Asthma Education
Environmental Allergen
control
Leukotriene Receptor Antagonist
(LTRA)
Montelukast
is associated with increased risk of
Major Depression
and
Suicide
https://www.fda.gov/news-events/press-announcements/fda-requires-stronger-warning-about-risk-neuropsychiatric-events-associated-asthma-and-allergy
Consider
Allergen Immunotherapy
Breathing Exercises in Asthma
Asthma Monoclonal Antibody
(
Asthma Biologic
)
Indicated in severe, refractory
Allergic Asthma
Management
Grouping (NIH recommendations)
Intermittent Asthma
Occasional exacerbations (Less than twice per week)
Mild Persistent Asthma
Frequent exacerbations (>twice weekly, but not daily)
Moderate Persistent Asthma
Daily symptoms with daily Beta
Agonist
use
Severe Persistent Asthma
Continuous Symptoms and frequent exacerbations
Management
Available Medications
All aerosolized
Inhaler
s should be used with a spacer
Without a spacer, medication delivery is inadequate
See
Spacer Devices for Asthma Inhalers
Inhaled Corticosteroid
s
Most important agents in reactive airway disease
Should be first-line agent in all persistent
Asthma
Maximize steroid dose before adding other agents
Ducharme (2002) BMJ 324:1545-8 [PubMed]
Mast Cell Stabilizer
s
Agents
Cromolyn Sodium
(
Intal
)
Nedocromil (Tilade)
Indications
Alternative antiinflammatory drug for age <5 years
Prophylactic agent for
Exercise
induced
Asthma
Cold-air-induced
Bronchi
al
Asthma
Beta Adrenergic Agonist
Short acting Rescue
Inhaler
(e.g.
Albuterol
)
Long acting scheduled
Inhaler
(e.g.
Serevent
)
See
SMART Asthma Management Protocol
Indicated for moderate to
Severe Asthma
Use as adjunct to
Inhaled Corticosteroid
s
Anticholinergic
s:
Ipratropium Bromide
(
Atrovent
)
Leukotriene Receptor Antagonist
(e.g.
Montelukast
)
Indicated as adjunct for moderate to
Severe Asthma
Do not use as a first line agent in most cases
Exception: Preschool children with
Allergic Asthma
Straub (2005) Chest 127:509-14 [PubMed]
Asthma Monoclonal Antibody
(
Asthma Biologic
Agents)
See
Asthma Biologic
Agents include Anti-IgE Therapy (
Omalizumab
) and anti-
Interleukin
4-5 agents
Indicated in severe refractory
Allergic Asthma
(
Type 2 Asthma
or
Eosinophilic Asthma
)
Allergen Immunotherapy
Consider in age 5 years and older with mild to moderate
Allergic Asthma
Contraindicated in
Severe Asthma
Other measures that are generally avoided
Theophylline
s
Rare use in modern Asthma Management
Vitamin D Supplement
ation is not effective in
Asthma
Martineau (2015) Thorax 70(5): 451-7 [PubMed]
Castro (2014) JAMA 311(20): 2083-91 [PubMed]
Soy Supplementation is not effective in
Asthma
Smith (2015) JAMA 311(20): 2033-43 [PubMed]
Management
Tapering down
Indications
Well controlled
Asthma
for at least 3 months
Exercise
caution in tapering if significant exacerbation risk
Serious exacerbation has occurred in the last year
Frequent and intermittent exacerbations related to triggers (e.g. allergies)
Technique
Step-down medications in the order that they were added
Combination agent (long acting
Bronchodilator
and
Corticosteroid
) tapering (e.g.
Advair
)
Start taper by decreasing
Corticosteroid
strength
Next, change combination agent to
Corticosteroid
only (e.g.
Flovent
only)
Next, decrease
Corticosteroid
Inhaler
strength by 25-50%
Next, discontinue if no exacerbations
Corticosteroid
agent
Start taper by decreasing
Corticosteroid
strength
Next, decrease number of doses per day (e.g. from 2 puffs AM and 2 puffs PM, to 2 puffs AM and 1 puff PM)
Next, discontinue if no exacerbations
Back-up plan
Asthma Action Plan
Rescue medication available at home (e.g.
Albuterol
)
Controller medication available at home to restart
Restart at last effective dose if rescue medication use more than twice weekly or worsening symptoms
References
(2017) Presc Lett 24(4): 22
Management
Exacerbations
See
Asthma Exacerbation
See
Asthma Exacerbation Home Management
See
Emergency Management of Asthma Exacerbation
See
Asthma Inpatient Management
See
Status Asthmaticus
See
Asthma Exacerbation Severity Evaluation
See
Asthma-Related Death Risk Factors
Resources
Asthma
Control Test (Children)
https://www.nationaljewish.org/NJH/media/pdf/pdf-Childhood_ACT.pdf
Asthma
Control Questionnaire (ACQ)
https://aaac.duhs.duke.edu/files/documents/Asthma%20control%20questionairre.pdf
Asthma
Therapy Assessment Questionnaire (ATAQ)
https://mydoctor.kaiserpermanente.org/ncal/Images/Pediatric%20Asthma%20Therapy_tcm75-70731.pdf
Prevention
See
Asthma Education
Weight loss in
Obesity
Exercise
Influenza Vaccine
yearly
Protection lags
Vaccine
by 2 weeks
Resources
Guidelines for the diagnosis and management of
Asthma
, expert panel 3 (2007)
https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report
References
Park (2017)
Asthma
Updates, Mayo Clinical Reviews, Rochester, MN
(2014) Presc Lett 21(12): 67-8
Kalister (2001) West J Med 174:415-20 [PubMed]
Narasimhan (2021) Am Fam Physician 103(5): 286-90 [PubMed]
Raymond (2023) Am Fam Physician 107(4): 358-68 [PubMed]
Type your search phrase here